World Molecular Diagnostics Market

World Molecular Diagnostics Market

This report analyzes the worldwide markets for Molecular Diagnostics in Millions of US$. The specific product segments analyzed are Infectious Disease Testing, Pharmacogenomics, and Cancer Screening. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 103 companies including many key and niche players worldwide such as Abbott Laboratories, Abbott Molecular, Applera Corporation, Celera, Biomérieux, CytoCore Inc., GE Healthcare, Gen-Probe Inc., Genzyme Corporation, Genzyme Genetics, MiraiBio, Inc., Nanogen, Novartis Vaccines & Diagnostics, Inc., QIAGEN N. V, Digene Corporation, Quest Diagnostics Incorporated, Roche Diagnostics, Siemens Healthcare Diagnostics, and Tecan Group Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

MOLECULAR DIAGNOSTICS MCP-1226
A GLOBAL STRATEGIC BUSINESS REPORT


CONTENTS


I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
Infectious Diseases Testing I-3
Pharmacogenomics I-4
Cancer Screening I-4

II. EXECUTIVE SUMMARY

1. Industry Overview II-1
Global Market Outlook II-1
Molecular Diagnostics - The Fastest Growing Medical
Diagnostic Technology II-1
New Applications Hold Promising Potential II-1
Automated Systems - Prime Target II-2
Infectious Disease Testing Drives the Diagnostics Market II-2
The Future in Store II-3

2. A Review of Medical Diagnostics Market II-4
Clinical Diagnostics Industry - Trends and Tendencies II-4
Table 1: Worldwide In Vitro Diagnostics (IVD) Market (2005 &
2006)- Percentage Breakdown by Value Sales for
Immunochemistry, Diabetes, Clinical Chemistry, Point-of-care
testing, Molecular Diagnostics, Hematology, Coagulation,
Urinalysis, and Others (includes corresponding Graph/Chart) II-5

Table 2: Leading Players in the Worldwide In Vitro
Diagnostics (IVD) Market (2005) - Percentage Breakdown by
Value Sales for Roche Diagnostics, Abbott Laboratories,
Johnson & Johnson, Bayer Diagnostics, Beckman Coulter, Dade
Behring, and Others (includes corresponding Graph/Chart) II-5

Table 3: Leading Players in the Worldwide Molecular
Diagnostics Market (2006) - Percentage Breakdown by Value
Sales for Roche Diagnostics, Chiron, Bayer Diagnostics,
GenProbe, Abbott Laboratories, Becton Dickinson, and Others
(includes corresponding Graph/Chart) II-6
Diagnostic Tests - Classification II-6
Table 4: Leading Players in the Worldwide Genetic Testing
Market (2006) - Percentage Breakdown by Value Sales for Roche
Diagnostics /Affymetrix, Abbott Laboratories, Bio-Rad
Laboratories, and Others(includes corresponding Graph/Chart) II-7
Nucleic Acid Diagnostics Market - An Overview II-7
Molecular Diagnostics - Growth Drivers II-8
Molecular Diagnostics - A Replacement and Enabling Technology II-9
Molecular Diagnostics for Lymphoid Malignancies II-9

3. Competitive Dynamics in the Molecular Diagnostics Market II-10
Key Players and Their Technologies II-10
The Top Tier II-10
Mid-Sized and Small Companies II-10

4. Market Trends & Issues II-12
Market Consolidations on the Way to Integrate in Vivo andin
Vitro Diagnostics II-12
Global Molecular Diagnostics on High Growth Curve II-12
Pharmaceutical Firms Carving Their Niche in Molecular
Diagnostic Market II-12
Towards Tailoring the Right Treatment for the Right Disease II-12
Disease-Specific Molecular Diagnostics to Deliver Improved
Clinical Outcomes II-13
Molecular Diagnostics and Intellectual Property II-13
Business Opportunities in the Offing II-13
Challenges Facing the Molecular Diagnostic Market II-14
Medical Training and Practice Challenges II-14
Shortcomings to Overcome II-14
Limited Reimbursements by Third Party Payers - A Stumbling Block II-15
Hurdles All the Way for Companies Eyeing Molecular Diagnostics II-15
Product Marketing - Key to Commercial Success II-16
Integration of Molecular Diagnostics into Therapeutics II-16
Molecular Diagnostics - Moving from Centralization to
Decentralization II-17
Migrating to Decentralized Format II-17
Going Ahead with Decentralization II-17

5. Product & Technology Overview II-19
Molecular Diagnostics - Definition & Scope II-19
Molecular Diagnostics - Impact on Healthcare II-19
Utility of Molecular Diagnostic Tests II-20
Background of Molecular Diagnostics II-20
Major Molecular Diagnostics Company Products II-20
Major Test Launches in Molecular Diagnostics II-21
Unabated Developments in Molecular Diagnostics Technology II-21
Signal Amplification Technologies II-21
PCR - New Developments II-21
Major Applications of Real-Time PCR II-22
Quantitative Real-Time PCR for Molecular Diagnostics II-22
Signal Detection and Quantification II-22
Quantitative Real-Time RT-PCR Analysis II-23
Applications of Quantitative Real-Time PCR Analysis II-23
Non-PCR Methods II-23
Other Signal Amplification Technologies II-23
DNA Probe Based Products II-23
Direct Detection of Specific Nucleic Acid Sequences II-24
Nucleic Acid Amplification and Detection II-24
DNA Sequencing and Gene Detection II-25
Arrays of Immobilized Probes (DNA Chips) in Gene Detection II-25
RNA Diagnostics II-26
Complementary Molecular Diagnostic Technologies II-26
Fluorescent in situ hybridization (FISH) II-26
DNA Biochips / Microarrays II-26
Biosensors II-27
Proteomic Technologies for Molecular Diagnostics II-28
Nanotechnology for Molecular Diagnostics II-28
Technologies on the Anvil II-29
Haplotype Analysis - A Distant Possibility II-29
Chronic Multi-Gene Defects Now Diagnosable II-29

6. An Insight into Applications of Molecular Diagnostics II-30
Infectious Diseases Testing II-30
Activity in the Field II-30
Identifying Multidrug Resistance II-31
Infectious Disease Treatment Monitoring II-31
Other Infectious Diseases Applications II-31
Genetic Disease Testing Applications II-31
Pharmacogenomics - Prognosis Based on Genomics II-32
Cancer Screening & Diagnosis II-32
Molecular Tests Lead the Way for Cancer IVD Market Growth II-33
Table 5: Worldwide Cancer Diagnostic Testing Market (2006):
Percentage Breakdown of Value Sales for Immunoassays,
Histology (IHC/ISH), Pap Testing, Flow Cytometry,
Prostate-Specific Antigen, Molecular Assays, and Fecal
Occult Blood Test (includes corresponding Graph/Chart) II-34
Other Testing Applications II-34

7. Product Developments/Introductions II-35
TMD Launches Test for K-ras Mutations in Colorectal Cancer
Patients II-35
CombiMatrix Releases Updated Version of Constitutional
Genetic Array Test II-35
Myriad Introduces TheraGuide 5-FU II-35
CMDX Unveils First HemeScan™ Prognostic II-35
CombiMatrix Introduces HemeScan™ MDS II-35
Genzyme Rolls Out Two New Molecular Tests II-36
Dade Behring Launches The Quadriga BeFree II-36
BD Diagnostics Introduces The BD Viper System II-36
Genzyme Introduces P53 Mutation Analysis II-36
CombiMatrix Molecular Diagnostics Rolls Out A New Melanoma Test II-36
Qiagen Launches Fast Cycling PCR Product Line II-36
Genzyme Releases Molecular Assay for Colorectal Cancer Patients II-36
Roche Diagnostics Launches LightCycler 480 System II-37
Roche Diagnostics Introduces AmpliChip CYP450 Test II-37
SEQUENOM Unveils iPLEX™ II-37
SEQUENOM Develops a Novel Process II-37
Cerner Corp Develops Cerner Millennium(R) PathNet Helix(TM) II-37
Roche Diagnostics Launches Amplicor HPV Test II-37
Gen-Probe Launches Procleix Ultrio Assay in Europe II-37
Gen-Probe Launches TIGRIS®DTS™ System II-38
BD Biosciences Introduces BD QZyme™ Assay II-38
Epoch Biosciences Releases MGB Eclipse™ II-38
QIAGEN Unveils BioRobot MDx DSP Device II-38
Digene Unveils DNAwithPap II-38
Exact Sciences Launches Non-Invasive Test for Colorectal Cancer II-38
TDT Introduces GCC-B1 Blood Test to Detect Colorectal Cancer II-38
AcroMetrix Joins Hands with Nabi to Introduce ViroSure II-39
Orchid Cellmark Introduces DNA Express Service II-39
Roche Develops New IVD Real-Time PCR Instrument II-39
Nanogen Rolls Out First Ever ASR II-39
Digene Introduces Hybrid Capture II-39
Digene’s Hybrid Capture 2 HPV DNA Test to Effectively
Identify Cervical Cancer II-39
PGD to Eliminate Human Eggs Affected with Alzheimer's Disease II-40
Esoterix Introduces New HCV Testing Program II-40
Gen-Probe Releases New APTIMA Combo 2 Assay II-40
Nycomed’s NeoSpect to Identify Suspected Lung Cancer II-40
DNAPrint Introduces New Services to Assist Forensic Market II-40
IMBG Develops an Efficient Procedure to Treat Diseases II-41

8. Recent Industry Activity II-42
Vermillion, Johns Hopkins Ink Agreements to Develop Molecular
Diagnostic Tests II-42
Beckman Coulter Inks Licensing Agreements with National
University of Ireland II-42
Roche Takes over BioVeris II-42
Siemens Acquires Dade Behring II-42
DiagnoCure Acquires Catalyst Oncology II-42
Burrill & Co Takes over Expression Diagnostics II-43
Solis Acquires Bertrand II-43
ParagonDx LLC Purchases Gentris Diagnostics II-43
Beckman Collaborates to Discover CVD Symptoms II-43
Exiqon to Take over Oncotech II-43
Roche to Acquire Ventana II-43
Qiagen Merges with Digene II-44
Qiagen & Bio One Capital Collaborates II-44
AGT & MAL Signs MoU II-44
Qiagen Obtains Licenses to Real-Time PCR II-44
Cepheid Purchases Sangtec II-44
Source MDx Collaborates with Pfizer II-45
Nanosphere Receives FDA Clearance for Second Molecular
Diagnostic Test II-45
QIAGEN Acquires eGene II-45
Quest Diagnostics Acquires AmeriPath II-45
Mayo and ILMN Team up to Develop Molecular Diagnostics for
Complex Diseases II-45
CHEO and ILMN Team up to Develop Molecular Diagnostics for
Newborn Screening II-45
Siemens Medical Solutions USA Sets Up Siemens Medical
Solutions Diagnostics II-46
Novartis Acquires Chiron II-46
Quest Diagnostics Acquires Focus Diagnostics II-46
Becton Dickinson Acquires GeneOhm II-46
Iris International Acquires Leucadia Technologies II-46
Predicant Biosciences Acquires Pathwork Informatics II-46
AmeriPath Acquires Rose Pathology Associates II-46
Nanogen Acquires Amplimedical’s Diagnostics Division II-47
Nanogen Acquires Immunoassay Test Business of Spectral
Diagnostics II-47
Fisher Scientific Acquires Athena II-47
Qiagen Acquires Genaco II-47
Bio-Rad Acquires Blackhawk BioSystems II-47
IRIS International Acquires Leucadia Technologies II-47
Qiagen Acquires Shenzhen PG Biotech II-47
Qiagen Acquires Artus GmbH II-48
Nanogen and Fisher Increases Agreement Tenure II-48
Qiagen Signs An Agreement with Gentra II-48
Qiagen Inks an Agreement with VLA II-48
Stratagene Signs an Agreement with AROS II-48
Bayer Inks an Agreement with Hamilton Company II-48
Prodesse and Invitrogen Sign a Pact II-49
Illumina Forms Collaboration with ReaMetrix II-49
PerkinElmer Signs an Agreement with Jacobi Medical II-49
UniPath and Roche Diagnostics Sign an Accord II-49
Qiagen Alliances with Eppendorf II-49
Olympus and Cangen Extends their Research Collaboration II-49
Toppan, Shimadzu and Third Wave Collaborate to Develop A POC
Molecular Diagnostic Instrument II-50
Focus Diagnostics Signs an Agreement with Stratagene II-50
Innogenetics Inks an Agreement with Roche Diagnostics II-50
The University of Goettingen, Bruker Daltonik and PANATecs
Collaborate to Develop New Molecular Diagnostic Assays for
Rheumatoid Arthritis II-50
Focus Diagnostics Enters into an Agreement with Luminex II-50
QIAGEN Expands Strategic Alliance with Protedyne II-51
Specialty Laboratories Teams Up with SEQUENOM and Siemens II-51
Gen-Probe Enters into a Licensing Agreement with Corixa II-51
Gen-Probe Inks a Supply and Purchase Agreement with F.
Hoffmann-La Roche II-51
Gen-Probe Enters into a Licensing Agreement with AdnaGen II-51
Roche Establishes New Polymerase Chain Reaction (PCR)
Manufacturing Center II-52
Ambion Establishes a Subsidiary in Japan II-52
Gen-Probe Gains FDA Approval for APTIMA® II-52
Blood Center of Southeastern Wisconsin Adopts Ambion’s
Signature™ CF 2.0 ASR II-52
Orchid Biosciences, Inc. Becomes Orchid Cellmark Inc II-52
Roche Acquires IGEN International II-52
GE Takes Over Amersham Plc II-52
Nanogen Acquires SYN•X PHARMA II-53
Nanogen Merges with Epoch Biosciences II-53
Sequenom Enters into Collaboration with Siemens II-53
TMD Joins Hands with University of Texas II-53
GE Global and Two other Companies Enters into a Joint
Research Collaboration II-53
Third Wave and BML Extend Partnership to Promote Molecular
Diagnostic Tests II-53
ViroLogic Signs an Agreement with ACLARA II-53
Abbott and BioGenex Sign an Agreement II-54
Novation Signs a Pact with Bayer Diagnostics II-54
Osmetech Enters into a Licensing Agreement with LGC Limited II-54
Licensing Agreement between DxS Ltd and Sangtec Molecular
Diagnostics II-54
EraGen Biosciences Strikes a Deal with Inter Medico II-54
Nanogen Bags Patent for Molecular Diagnostics and Optical
Waveguides Systems II-54
Gen-Probe Secures Regulatory Approval for PROCLEIX ® ULTRIO™
Assay II-55
Gen-Probe Bags FDA Approval to Use TIGRIS DTS System for STD
Testing II-55
Gen-Probe Acquires Majority Stake in MLT II-55
AmeriPath in Strategic Alliance with Roche II-55
Abbott and Promega to Offer Nucleic Acid Extraction Products II-55
Ambion RNA to Offer Services Through BBI II-55
STMicroelectronics Inks an Agreement with Mobidiag II-56
BBI Contracts with IDS II-56
Focus to Assist FDA in Evaluation of Antimicrobial Resistance II-56
Bayer Acquires Rights to Detect HCV and HIV Antibodies II-56
Cenetron in Strategic Alliance with Roche II-56
Saint Luke's Health System in Alliance with Roche II-56
US LABS Adds Gene Expression Profiling Capabilities on (FFPE)
Tissue II-57
Bayer Acquires Visible Genetics II-57
Qiagen Enters into an Agreement with RMS II-57
Dabur Starts a New Molecular Diagnostic Lab II-57
Roche Gains Rights for Cervical-Cancer Testing Market II-57
Ventana Acquires License From MDI II-58
Genzyme Genetics Gains Rights for Genzyme Molecular’s Cancer
Diagnostics II-58
Abbott in Strategic Alliance with Celera II-58
MDI and DiagnoCure Join Hands to Integrate ImmunoCyt/uCyt
with InPath II-58
MDI and PMI to Jointly Promote Lung Cancer Detection System II-58
MDI in Agreement with Esoterix II-59
MDI to Expand Product Base in China II-59
Abbott and Tecan to Offer Devices for Molecular Diagnostic
Assays II-59
Invirion Extends Licensing Agreement with MDI II-59
Ambion RNA Grants License to Celera II-59
Morewood and IT&M to Introduce New Micro Array System II-59
Ambion RNA Constructs New Manufacturing Facility II-60
LabCorp Teams up with Celera II-60
Athena Launches New DNA Testing for TSC II-60
Genezyme Genetics Expands Cancer Testing Services II-60
Promega Teams Up with Abbott II-60
ChromaVision and Ventana Join Hands to Market Testing Process
that Identifies HPV II-60
OraSure in Agreement with Abbott II-61
Nanogen and Bionomics to Jointly Develop IVD for Epilepsy II-61
DiagnoCure and Compugen Join Hands to Develop Tests to
Identify Epithelial Cancers II-61
OraSure Gets FDA Approval for OraQuick Rapid HIV-1 Test II-61
Ampersand and Accumed Merged to Form MDI II-61
Abbott Acquires Vysis II-61
Millennium and Abbott Forge 5-Year Drug Deal II-62
Bode Enters into Agreement to Undertake DNA Testing II-62
BD Contracts with TriPath to Develop Molecular Diagnostics II-62
TriPath Installs New Interactive System II-62
Archemix in Strategic Alliance with RPI II-62
AmeriPath Strengthens Relationship with Genomics Collaborative II-63
Cepheid and Infectio Join Hands to Form Aridia II-63
Myriad Enters into Agreement with NCI II-63
Nanogen Gains Further Rights for Electronic Microarray Technology II-63

9. Focus on Select Global Players II-64
Abbott Laboratories (US) II-64
Abbott Molecular II-64
Applera Corporation (US) II-64
Celera (US) II-64
Biomérieux (France) II-65
CytoCore Inc (US) II-65
GE Healthcare (US) II-66
Gen-Probe Inc (US) II-66
Genzyme Corporation (US) II-66
Genzyme Genetics (US) II-67
MiraiBio, Inc. (US) II-67
Nanogen (US) II-67
Novartis Vaccines & Diagnostics, Inc. (US) II-67
QIAGEN N. V (The Netherlands) II-68
Digene Corporation (USA) II-68
Quest Diagnostics Inc. (US) II-69
Roche Diagnostics (Switzerland) II-69
Siemens Healthcare Diagnostics (US) II-69
Tecan Group Ltd. (Switzerland) II-70

10. Global Market Perspective II-71
Table 6: World Recent Past, Current & Future Market Analysis
for Molecular Diagnostics by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan) and Rest of
World Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) II-71

Table 7: World Long-term Projections for Molecular Diagnostics
by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan) and Rest of World Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) II-72

Table 8: World 10-Year Perspective for Molecular Diagnostics
by Geographic Region - Percentage Breakdown of Dollar Sales
for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan)
and Rest of World Markets for Years 2003, 2008 & 2012(includes
corresponding Graph/Chart) II-73

Table 9: World Recent Past, Current & Future Market Analysis
for Molecular Diagnostics (Infectious Disease Testing) by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), and Rest of World Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2000
through 2010 (includes corresponding Graph/Chart) II-74

Table 10: World Long-term Projections for Molecular
Diagnostics (Infectious Disease Testing) by Geographic Region
- US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
and Rest of World Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-75

Table 11: World 10-Year Perspective for Molecular Diagnostics
(Infectious Disease Testing) by Geographic Region - Percentage
Breakdown of Dollar Sales for US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), and Rest of World Markets for
Years 2003, 2008 & 2012 (includes corresponding Graph/Chart) II-76

Table 12: World Recent Past, Current & Future Market Analysis
for Molecular Diagnostics (Pharmacogenomics) by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), and Rest of World Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) II-77

Table 13: World Long-term Projections for Molecular
Diagnostics (Pharmacogenomics) by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific (excluding Japan), and
Rest of World Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-78

Table 14: World 10-Year Perspective for Molecular Diagnostics
(Pharmacogenomics) by Geographic Region - Percentage Breakdown
of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), and Rest of World Markets for Years 2003,
2008 & 2012 (includes corresponding Graph/Chart) II-79

Table 15: World Recent Past, Current & Future Market Analysis
for Molecular Diagnostics (Cancer Screening) by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), and Rest of World Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) II-80

Table 16: World Long-term Projections for Molecular
Diagnostics (Cancer Screening) by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific (excluding Japan) and
Rest of World Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-81

Table 17: World 10-Year Perspective for Molecular Diagnostics
(Cancer Screening) by Geographic Region - Percentage Breakdown
of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), and Rest of World Markets for Years 2003,
2008 & 2012 (includes corresponding Graph/Chart) II-82

III. MARKET

1. United States III-1
A.Market Analysis III-1
A Precursor to the Molecular Diagnostics Market in the US III-1
Molecular Diagnostics Heavily Tied to Proteomics and Genomics III-1
Burgeoning Potential for Genetic Testing III-1
Regulatory Environment III-2
Regulations Out for Molecular Diagnostic Testing of HPV III-2
Limited Reimbursements - A Major Hindrance III-3
Key Players III-3
Product Launches III-7
Strategic Developments III-12
B.Market Analytics III-29
Table 18: US Recent Past, Current & Future Analysis for
Molecular Diagnostics by Product Segment - Infectious
Disease Testing, Pharmacogenomics, and Cancer Screening
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-29

Table 19: US Long-term Projections for Molecular Diagnostics
by Product Segment - Infectious Disease Testing,
Pharmacogenomics, and Cancer Screening Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart) III-29

Table 20: US 10-Year Perspective for Molecular Diagnostics
by Product Segment - Percentage Breakdown of Dollar Sales
for Infectious Disease Testing, Pharmacogenomics, andCancer
Screening Markets for 2003, 2008 & 2012(includes
corresponding Graph/Chart) III-30

2. Canada III-31
A.Market Analysis III-31
Strategic Developments III-31
B.Market Analytics III-32
Table 21: Canadian Recent Past, Current & Future Analysis
for Molecular Diagnostics by Product Segment - Infectious
Disease Testing, Pharmacogenomics, and Cancer Screening
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-32

Table 22: Canadian Long-term Projections for Molecular
Diagnostics by Product Segment - Infectious Disease Testing,
Pharmacogenomics, and Cancer Screening Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart III-32

Table 23: Canadian 10-Year Perspective for Molecular
Diagnostics by Product Segment - Percentage Breakdown of
Dollar Sales for Infectious Disease Testing,
Pharmacogenomics, and Cancer Screening Markets for 2003,
2008 & 2012 (includes corresponding Graph/Chart) III-33

3. Japan III-34
A.Market Analysis III-34
Strategic Developments III-34
B.Market Analytics III-35
Table 24: Japanese Recent Past, Current & Future Analysis
for Molecular Diagnostics by Product Segment - Infectious
Disease Testing, Pharmacogenomics, and Cancer Screening
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-35

Table 25: Japanese Long-term Projections for Molecular
Diagnostics by Product Segment - Infectious Disease Testing,
Pharmacogenomics, and Cancer Screening Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2011 through 2015 (includes corresponding Graph/Chart) III-35

Table 26: Japanese 10-Year Perspective for Molecular
Diagnostics by Product Segment - Percentage Breakdown of
Dollar Sales for Infectious Disease Testing,
Pharmacogenomics, and Cancer Screening Markets for 2003,
2008 & 2012 (includes corresponding Graph/Chart) III-36

4. Europe III-37
A.Market Analysis III-37
Insight into Molecular Diagnostics Markets in Europe III-37
Table 27: European Molecular Diagnostics Market (2006) -
Market Shares of Leading Players by Value Sales for Roche
Diagnostics, Abbott Diagnostics, Bayer Diagnostics, Becton
Dickinson, Digene Diagnostics, BioMerieux and Others
(includes corresponding Graph/Chart) III-38
Product Launches III-38
B.Market Analytics III-39
Table 28: European Recent Past, Current & Future Analysis
for Molecular Diagnostics by Geographic Region - France,
Germany, Italy, UK, and Rest of Europe Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2010 (includes corresponding Graph/Chart) III-39

Table 29: European Long-term Projections for Molecular
Diagnostics by Geographic Region - France, Germany, Italy,
UK, and Rest of Europe Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2011 through
2015 (includes corresponding Graph/Chart) III-40

Table 30: European Recent Past, Current & Future Analysis
for Molecular Diagnostics by Product Segment - Infectious
Disease Testing, Pharmacogenomics, and Cancer Screening
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-40

Table 31: European Long-term Projections for
Molecular(includes corresponding Graph/Chart) Diagnostics by
Product Segment -Infectious Disease Testing,
Pharmacogenomics, and Cancer Screening Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-41

Table 32: European 10-Year Perspective for Molecular
Diagnostics by Geographic Region - Percentage Breakdown of
Dollar Sales for France, Germany, Italy, UK, and Rest of
Europe Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-41

Table 33: European 10-Year Perspective for Molecular
Diagnostics by Product Segment - Percentage Breakdown of
Dollar Sales for Infectious Disease Testing,
Pharmacogenomics, and Cancer Screening Markets for 2003,
2008 & 2012 (includes corresponding Graph/Chart) III-42

4a. France III-43
A.Market Analysis III-43
bioMérieux - A Key French Player III-43
Strategic Development III-43
B.Market Analytics III-44
Table 34: French Recent Past, Current & Future Analysis for
Molecular Diagnostics by Product Segment - Infectious
Disease Testing, Pharmacogenomics, and Cancer Screening
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-44

Table 35: French Long-term Projections for Molecular
Diagnostics by Product Segment - Infectious Disease Testing,
Pharmacogenomics, and Cancer Screening Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-44

Table 36: French 10-Year Perspective for Molecular
Diagnostics by Product Segment - Percentage Breakdown of
Dollar Sales for Infectious Disease Testing,
Pharmacogenomics, and Cancer Screening Markets for 2003,
2008 & 2012 (includes corresponding Graph/Chart) III-45

4b. Germany III-46
Market Analysis III-46
Table 37: German Recent Past, Current & Future Analysis for
Molecular Diagnostics by Product Segment - Infectious
Disease Testing, Pharmacogenomics, and Cancer Screening
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-46

Table 38: German Long-term Projections for Molecular
Diagnostics by Product Segment - Infectious Disease Testing,
Pharmacogenomics, and Cancer Screening Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-47

Table 39: German 10-Year Perspective for Molecular
Diagnostics by Product Segment - Percentage Breakdown of
Dollar Sales for Infectious Disease Testing,
Pharmacogenomics, and Cancer Screening Markets for 2003,
2008 & 2012 (includes corresponding Graph/Chart) III-47

4c. Italy III-48
Market Analysis III-48
Table 40: Italian Recent Past, Current & Future Analysis for
Molecular Diagnostics by Product Segment - Infectious
Disease Testing, Pharmacogenomics, and Cancer Screening
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-48

Table 41: Italian Long-term Projections for Molecular
Diagnostics by Product Segment - Infectious Disease Testing,
Pharmacogenomics, and Cancer Screening Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-49

Table 42: Italian 10-Year Perspective for Molecular
Diagnostics by Product Segment - Percentage Breakdown of
Dollar Sales for Infectious Disease Testing,
Pharmacogenomics, and Cancer Screening Markets for 2003,
2008 & 2012 (includes corresponding Graph/Chart) III-49

4d. United Kingdom III-50
A.Market Analysis III-50
Product Launch III-50
Strategic Development III-50
B.Market Analytics III-51
Table 43: UK Recent Past, Current & Future Analysis for
Molecular Diagnostics by Product Segment - Infectious
Disease Testing, Pharmacogenomics, and Cancer Screening
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-51

Table 44: UK Long-term Projections for Molecular Diagnostics
by Product Segment - Infectious Disease Testing,
Pharmacogenomics, and Cancer Screening Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-51

Table 45: UK 10-Year Perspective for Molecular Diagnostics
by Product Segment - Percentage Breakdown of Dollar Sales
for Infectious Disease Testing, Pharmacogenomics, and
Cancer Screening Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-52

4e. Rest of Europe III-53
A.Market Analysis III-53
Key Players III-53
Product Launches III-54
Strategic Developments III-55
B.Market Analytics III-58
Table 46: Rest of Europe Recent Past, Current & Future
Analysis for Molecular Diagnostics by Product Segment -
Infectious Disease Testing, Pharmacogenomics, and Cancer
Screening Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-58

Table 47: Rest of Europe Recent Past, Current & Future
Analysis for Molecular Diagnostics by Product Segment -
Infectious Disease Testing, Pharmacogenomics, and Cancer
Screening Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2011 through 2015
(includes corresponding Graph/Chart) III-58

Table 48: Rest of Europe 10-Year Perspective for Molecular
Diagnostics by Product Segment - Percentage Breakdown of
Dollar Sales for Infectious Disease Testing,
Pharmacogenomics, and Cancer Screening Markets for 2003,
2008 & 2012 (includes corresponding Graph/Chart) III-59

5. Asia-Pacific III-60
A.Market Analysis III-60
Indian Diagnostic Market III-60
Strategic Developments III-60
B.Market Analytics III-61
Table 49: Asia-Pacific Recent Past, Current & Future
Analysis for Molecular Diagnostics by Product Segment -
Infectious Disease Testing, Pharmacogenomics, and Cancer
Screening Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-61

Table 50: Asia-Pacific Recent Past, Current & Future
Analysis for Molecular Diagnostics by Product Segment -
Infectious Disease Testing, Pharmacogenomics, and Cancer
Screening Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2011 through 2015
(includes corresponding Graph/Chart) III-62

Table 51: Asia-Pacific 10-Year Perspective for Molecular
Diagnostics by Product Segment - Percentage Breakdown of
Dollar Sales for Infectious Disease Testing,
Pharmacogenomics, and Cancer Screening Markets for 2003,
2008 & 2012 (includes corresponding Graph/Chart) III-62

6. Rest of World III-63
Market Analysis III-63
Table 52: Rest of World Recent Past, Current & Future
Analysis for Molecular Diagnostics by Product Segment -
Infectious Disease Testing, Pharmacogenomics, and Cancer
Screening Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-63

Table 53: Rest of World Long-term Projections for Molecular
Diagnostics by Product Segment - Infectious Disease
Testing, Pharmacogenomics and Cancer Screening Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-64

Table 54: Rest of World 10-Year Perspective for Molecular
Diagnostics by Product Segment - Percentage Breakdown of
Dollar Sales for Infectious Disease Testing,
Pharmacogenomics, and Cancer Screening Markets for 2003,
2008 & 2012 (includes corresponding Graph/Chart) III-64

IV. COMPETITIVE LANDSCAPE